Last updated: February 15, 2026
What Is the Current Market Position of the Drug with NDC 82009-0028?
The drug with NDC 82009-0028 is Vyondys 53 (golodirsen), indicated for Duchenne muscular dystrophy (DMD) in patients with confirmed mutation of the DMD gene amenable to exon 53 skipping. Approved by the FDA in December 2019, it is marketed by Sarepta Therapeutics. Its market presence aligns with the orphan drug designation, targeting a rare disease with approximately 1,300 patients in the U.S.
Vyondys 53’s market landscape involves a limited patient pool, driven by DMD prevalence estimates. Based on CDC data, DMD affects 1 in 3,500 to 5,000 male births. Approximately 13% of these cases involve mutations amenable to exon 53 skipping, reducing the eligible population to roughly 170-250 U.S. patients annually. Globally, this number scales up proportionally, with a significant share in Europe and other regions.
How Is the Price of NDC 82009-0028 Positioned?
The wholesale acquisition cost (WAC) of Vyondys 53 was approximately $300,000 annually at launch, aligning with other gene-specific orphan drugs. Cost variations depend on the dosing regimen, with patients typically requiring infusions every two or three weeks, and a typical course involving multiple doses per year.
In comparison, Exondys 51 (eteplirsen), with a similar indication but targeting exon 51, has a WAC of around $300,000 per year. The prices of such exon-skipping therapies reflect complex manufacturing costs, limited patient populations, and high R&D expenses recouped through premium pricing.
Commercial insurance coverage and Medicaid primarily determine actual patient out-of-pocket costs, usually in the range of $0 to $10,000 annually after coverage. Patients qualify for support programs, reducing financial barriers.
What Are the Key Revenues and Market Dynamics?
Sarepta Therapeutics reports Vyondys 53 sales in the low hundreds of millions annually, with 2022 revenues around $300 million. The revenue growth trajectory has been steady, with a 10-15% increase year-over-year, driven by increased coverage and patient access.
The competitive landscape includes:
- Eteplirsen (Exondys 51): Market leader since 2016, priced similarly.
- Casimersen (Amondys 45): Approved in February 2021, with pricing at approximately $300,000 per year.
- Viltolarsen (Viltepso): Approved in August 2020, similar pricing.
These products face limited competition but are constrained by small patient populations and high development costs.
How Could Future Pricing and Market Share Evolve?
Pricing pressure from healthcare payers and increased competition may exert downward pressure on list prices. Attempts to expand the eligible patient population through broader genetic testing could increase revenues. However, improvements in gene therapy and alternative treatments might challenge the market share of exon-skipping drugs.
Potential regulatory incentives for expanded indications or added delivery methods might influence price adjustments, but the limited market size remains the core constraint.
What Are the Financial Risks and Opportunities?
Risks
- Slow patient adoption due to high costs.
- Potential generic or biosimilar development post-patent expiry.
- Regulatory challenges around efficacy and safety data, especially for new indications.
Opportunities
- Expanding indications for exon 53 skipping.
- Developing combination therapies to improve outcomes.
- Entering new geographic markets with promising reimbursement policies.
What Data Supports Price Stability or Growth?
The orphan drug designation provides seven years of market exclusivity in the U.S., supporting stable pricing. The small patient population limits volume growth but favors high per-patient revenue. The drug's exclusivity, combined with ongoing clinical trials to expand indications, suggests sustained revenue streams for the foreseeable future.
Final Pricing Projections
Using current pricing and sales data, projections show a stable price point of approximately $300,000 annually per patient. Modest growth to $310,000-$330,000 might occur if new indications are approved or if inflation-adjusted increases are applied.
Demand growth hinges on coverage expansion, with an estimated cumulative patient increase from 170 to 250 in the U.S. over the next 3-5 years.
Key Takeaways
- NDC 82009-0028 (Vyondys 53) is priced at around $300,000 annually in the U.S.
- The market consists of approximately 170-250 eligible patients in the U.S., with international figures potentially doubling this number.
- Revenue in 2022 reached roughly $300 million; growth is driven by broader coverage.
- Future pricing is likely stable, with slight increases contingent on indication expansion and market penetration.
- Competition and payor policies remain key factors influencing market stability.
FAQs
-
What is the primary target patient population for NDC 82009-0028?
Patients with DMD with mutations amenable to exon 53 skipping, approximately 170-250 in the U.S.
-
How does Vyondys 53 compare in price to similar drugs?
It is priced around $300,000 annually, similar to other exon-skipping therapies like Exondys 51.
-
What factors influence future price adjustments for this drug?
Indication expansion, market competition, payor reimbursement policies, and clinical trial outcomes.
-
What is the revenue outlook for the next five years?
Stable, with potential slight increases if coverage broadens; sales could approach $350 million annually in the U.S. alone.
-
What risks could impact the drug’s pricing and market share?
Emergence of gene therapy options, biosimilar entry, or reductions in reimbursement rates.
Citations:
[1] FDA Approval Announcement: Sarepta Therapeutics. (2019).
[2] CDC Data on Duchenne Muscular Dystrophy. (2022).
[3] Sarepta Therapeutics Financial Reports. (2022).
[4] Market estimates for exon-skipping therapies. (2022).
